BCL2 and acute lymphoblastic leukemia: This case series presents a strong foundation for further prospective studies that could assess the efficacy of combining HMAs with BCL-2 inhibitors, not only in the post-transplant setting but also for T-ALL patients who fail to respond to standard treatment options.